Furthermore, ALKBH5-targeted siRNA delivered via vesicle-like nanoparticles or anti-DKK1 treatment enhances the efficacy of anti-PD-1 therapy by promoting antitumor immunity and restraining CRC growth (43) (Figure 2). Here, DKK1 is linked to colorectal carcinoma.